Furthermore, on the single gene level, we identified the androgen receptor (AR) as a crucial positive correlator with inherent resistance to three of the four types of treatment—a candidate which is already successfully therapeutically addressed in several cancer entities, such as prostate cancer [58, 61, 85], and thus is eligible to rapid evaluation in glioblastoma [52]. This evidence concerns the gene AR and prostate cancer.